Apavadis

The company

  • Spin-off of the IRCC in Candiolo (Turin); established in 2006, it operates in the field of tumour diagnosis and therapy.
  • Apavadis’ products are peptides that bind to and inhibit the function of aminopeptidase A (APA project) or bind with the complex E-cadherin/α6 integrin (Project META). Applications include hepatic tumors, but also endometriosis.
  • Two patents filed in 2004 and 2006.
  • Selected publication: “Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma”, Loi et al (2010) J. Control Release 145: 66-73
    [link:http://www.ncbi.nlm.nih.gov/pubmed/20346382]

Current Status

  • Validated APA e META as tumoral target.
  • Demonstrated that APA and META peptides specifically bind to and limit the growth of target tumors in vitro and in vivo.
  • Feasibility agreement with international companies in the field of imaging and radiopharmaceuticals to evaluate the use of APA peptides as diagnostic in oncology.